Inotuzumab Ozogamicin

證據等級: L5

預測適應症: 10 個

Inotuzumab Ozogamicin: From B-Cell Precursor Acute Lymphoblastic Leukemia to Drug-Induced Osteoporosis

One-Sentence Summary

Inotuzumab ozogamicin is an anti-CD22 antibody-drug conjugate (ADC) approved internationally for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and is currently not registered in Singapore. The TxGNN model predicts it may be effective for Drug-Induced Osteoporosis as its highest-ranked repurposing candidate (score: 98.24%), however, with 0 clinical trials and 0 directly relevant publications supporting this direction, the evidence base remains at model prediction only.

Quick Overview

Item	Content
Original Indication	Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Predicted New Indication	Drug-Induced Osteoporosis
TxGNN Prediction Score	98.24%
Evidence Level	L5
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Inotuzumab ozogamicin is a targeted antibody-drug conjugate composed of a humanized anti-CD22 IgG4 monoclonal antibody covalently linked to calicheamicin — a potent cytotoxic natural product that induces irreversible double-strand DNA breaks upon intracellular release. CD22 is a cell-surface glycoprotein expressed predominantly on mature B lymphocytes and on the blast cells of most B-cell precursor ALL patients. After the ADC binds to CD22 and is internalized, the calicheamicin payload is released, selectively killing CD22-expressing cells. This narrow mechanism of action is what makes the drug effective against B-cell malignancies.

Drug-induced osteoporosis, by contrast, is a metabolic bone disease driven by osteoclast/osteoblast imbalance, typically triggered by agents such as glucocorticoids, aromatase inhibitors, or androgen deprivation therapy. Its core pathophysiology revolves around RANKL/OPG signaling, vitamin D and calcium metabolism dysregulation, and direct suppression of osteoblast activity. There is no established direct link between the CD22 antigen or calicheamicin's DNA-damaging mechanism and bone remodeling pathways.

The high TxGNN knowledge graph score (98.24%) is most likely driven by indirect graph connectivity — for example, B cells are known to influence RANKL expression in the bone microenvironment, which in turn regulates osteoclastogenesis. While this indirect path exists biologically, it does not constitute a therapeutically actionable connection for an ADC targeting CD22. In practice, inotuzumab ozogamicin itself causes significant thrombocytopenia and hepatic sinusoidal obstruction syndrome, making safety in a non-oncology setting a further concern. This prediction should be considered a speculative, graph-topology artifact rather than a biologically grounded repurposing hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Note on Rank 5 (Breast Tumor Luminal A/B): The evidence search for that indication retrieved 19 PubMed results; however, upon individual review, all publications relate to B-cell biology, hepatitis B vaccine studies, or unrelated topics. These represent keyword contamination (the letter "B" triggering B-cell–related literature) and contain no evidence supporting inotuzumab ozogamicin use in breast cancer.

Singapore Market Information

Inotuzumab ozogamicin is not registered in Singapore. No marketing authorizations or product licenses were identified. Clinicians requiring access would need to pursue special access channels (e.g., clinical trial enrollment or compassionate use pathways), subject to HSA approval.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted cytotoxic — Antibody-Drug Conjugate (ADC); payload is calicheamicin, a DNA double-strand break inducer (enediyne class)
Myelosuppression Risk	High — Thrombocytopenia is a dose-limiting toxicity reported in >50% of patients in pivotal trials; neutropenia and febrile neutropenia are also common
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (monitor for thrombocytopenia and neutropenia), liver function tests with particular attention to sinusoidal obstruction syndrome (SOS/VOD), total bilirubin, renal function, coagulation profile
Handling Protection	Must follow cytotoxic/hazardous drug handling regulations; ADC preparation requires specialized pharmacy biosafety protocols (closed-system transfer devices recommended)

Safety Considerations

Please refer to the package insert for complete safety information. Given that inotuzumab ozogamicin itself causes dose-limiting thrombocytopenia and carries a black-box warning for hepatic sinusoidal obstruction syndrome (SOS/VOD) in international labeling, extrapolation to non-oncology indications such as drug-induced osteoporosis raises significant safety concerns that would need to be thoroughly characterized before any clinical evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinically coherent mechanistic link between inotuzumab ozogamicin's anti-CD22 mode of action and the pathophysiology of drug-induced osteoporosis. All 10 TxGNN-predicted indications for this drug return an L5 evidence level (model prediction only, zero supporting trials or literature), and several predictions — including breast cancer subtypes, platelet disorders, pseudo-von Willebrand disease, and infectious bovine rhinotracheitis — exhibit clear mechanistic implausibility or fall entirely outside the scope of human oncology. The drug's known serious toxicities (thrombocytopenia, hepatotoxicity) further complicate any non-oncology repurposing scenario.

To proceed, the following is needed:

Mechanistic validation: Identify a biologically plausible and testable hypothesis connecting CD22/B-cell biology to bone resorption (e.g., B-cell–mediated RANKL upregulation in steroid-induced osteoporosis models)
Preclinical proof-of-concept: In vitro or in vivo studies demonstrating that anti-CD22 targeting reduces bone loss in drug-induced osteoporosis animal models
MOA data retrieval: Query DrugBank API to obtain complete mechanism-of-action data for formal mechanistic analysis
Safety package review: Obtain and parse the full prescribing information (package insert) to complete S1 safety screening, including warnings, contraindications, and special population data
Regulatory pathway assessment: Evaluate feasibility of Singapore registration or compassionate use given current non-marketed status and the nature of the proposed indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.